Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Monotherapy or in combination w/ MTX for the treatment of active psoriatic arthritis in adults who have responded inadequately to, or who are intolerant to ≥1 DMARD therapies. Treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Treatment of active non-radiographic axial spondyloarthritis w/ objective signs of inflammation as indicated by elevated C‑reactive protein &/or MRI in adults who have responded inadequately to NSAIDs.
Areas of the skin that show psoriasis should be avoided as inj sites. Discontinue treatment immediately in case of serious hypersensitivity reaction. Increased rate of infections eg, URTI, oral candidiasis, conjunctivitis, & tinea infections. Caution in patients w/ clinically important chronic infection or history of recurrent infection. Must not be given to patients w/ active TB. Not recommended in patients w/ inflammatory bowel disease. Do not use w/ live vaccines. Has not been studied in patients w/ renal or hepatic impairment. Women of childbearing potential should use effective contraception during treatment & for at least 10 wk after treatment. Preferable to avoid use during pregnancy. Discontinue breast-feeding or discontinue therapy. Limited information in elderly ≥75 yr.
Sign Out
